| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 8.24▲ | 8.12▲ | 8.13▲ | 7.78▲ | 7.41▲ |
| MA10 | 8.11▲ | 7.98▲ | 7.92▲ | 7.59▲ | 6.09▲ |
| MA20 | 7.97▲ | 7.84▲ | 7.74▲ | 7.28▲ | 4.90▲ |
| MA50 | 7.69▲ | 7.53▲ | 7.57▲ | 5.87▲ | 6.07▲ |
| MA100 | 7.51▲ | 7.44▲ | 7.53▲ | 4.92▲ | 6.53▲ |
| MA200 | 7.49▲ | 7.10▲ | 6.51▲ | 6.07▲ | 17.79▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.033▲ | 0.045▲ | 0.059▲ | 0.006▲ | 0.533▲ |
| RSI | 63.863▲ | 66.039▲ | 65.012▲ | 65.117▲ | 64.652▲ |
| STOCH | 79.302 | 90.000▲ | 92.268▲ | 71.530 | 80.047▲ |
| WILL %R | -21.622▲ | -12.183▲ | -12.183▲ | -7.921▲ | -3.189▲ |
| CCI | 123.785▲ | 178.660▲ | 190.935▲ | 145.047▲ | 125.175▲ |
|
Friday, August 08, 2025 09:15 PM
Kala Pharmaceuticals ( ($KALA) ) has released its Q2 earnings. Here is a breakdown of the information Kala Pharmaceuticals presented to its ...
|
|
Friday, August 08, 2025 09:15 PM
Kala Pharmaceuticals ( ($KALA) ) has released its Q2 earnings. Here is a breakdown of the information Kala Pharmaceuticals presented to its ...
|
|
Friday, August 08, 2025 05:19 AM
Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 8.01 | 8.45 | 7.51 | 8.32 | 134,983 |
| 14/08/25 | 7.87 | 8.14 | 7.38 | 8.07 | 72,159 |
| 13/08/25 | 7.40 | 7.98 | 7.40 | 7.87 | 71,093 |
| 12/08/25 | 7.20 | 7.814 | 7.20 | 7.44 | 49,190 |
| 11/08/25 | 7.32 | 7.6886 | 7.13 | 7.20 | 47,710 |
| 08/08/25 | 7.12 | 7.71 | 7.0502 | 7.38 | 108,492 |
| 07/08/25 | 7.46 | 7.68 | 7.00 | 7.16 | 110,169 |
| 06/08/25 | 7.70 | 7.92 | 7.25 | 7.32 | 84,315 |
| 05/08/25 | 7.30 | 7.95 | 7.00 | 7.70 | 171,974 |
| 04/08/25 | 7.49 | 7.65 | 6.9641 | 7.45 | 85,166 |
|
|
||||
|
|
||||
|
|